BRPI0800485A8 - vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose - Google Patents

vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose Download PDF

Info

Publication number
BRPI0800485A8
BRPI0800485A8 BRPI0800485A BRPI0800485A BRPI0800485A8 BR PI0800485 A8 BRPI0800485 A8 BR PI0800485A8 BR PI0800485 A BRPI0800485 A BR PI0800485A BR PI0800485 A BRPI0800485 A BR PI0800485A BR PI0800485 A8 BRPI0800485 A8 BR PI0800485A8
Authority
BR
Brazil
Prior art keywords
leishmaniasis
viral vectors
recombinant viral
vaccine composition
vaccination
Prior art date
Application number
BRPI0800485A
Other languages
English (en)
Inventor
Paula Salles Moura Fernandes Ana
Da Fonseca Guimarães Flavio
Bruna Romero Oscar
Tostes Gazzinelli Ricardo
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0800485A priority Critical patent/BRPI0800485B8/pt
Priority to CN201710930134.7A priority patent/CN108014330A/zh
Priority to MX2010007876A priority patent/MX2010007876A/es
Priority to CN200980105562XA priority patent/CN102036681A/zh
Priority to PCT/BR2009/000014 priority patent/WO2009089605A1/en
Publication of BRPI0800485A2 publication Critical patent/BRPI0800485A2/pt
Publication of BRPI0800485A8 publication Critical patent/BRPI0800485A8/pt
Publication of BRPI0800485B1 publication Critical patent/BRPI0800485B1/pt
Publication of BRPI0800485B8 publication Critical patent/BRPI0800485B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

vetores virais recombinantes, composição vacinal para leishmaniose e método profilático/terapêutico de vacinação para leishmaniose. a presente invenção diz respeito a vetores virais recombinantes que expressam o antígeno a2 de leishmania e composições vacinais úteis para serem utilizadas como vacina contra leishmaniose. a invenção ainda revela um método de vacinação dose-reforço (prime-boost) que utiliza vetores adenovirais e poxvirais para a imunização de mamíferos contra leishmaniose. tal método permite a distinção sorológica entre indivíduos vacinados e infectados por meio de testes de elisa ou imunofluorescência convencionais empregando antígenos de formas promastigotas de leishmania.
BRPI0800485A 2008-01-17 2008-01-17 vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose BRPI0800485B8 (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0800485A BRPI0800485B8 (pt) 2008-01-17 2008-01-17 vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
CN201710930134.7A CN108014330A (zh) 2008-01-17 2009-01-16 用于利什曼病的重组病毒载体和疫苗组合物
MX2010007876A MX2010007876A (es) 2008-01-17 2009-01-16 Vectores virales recombinantes y composicion de vacuna para leishmaniasis.
CN200980105562XA CN102036681A (zh) 2008-01-17 2009-01-16 用于利什曼病的重组病毒载体和疫苗组合物
PCT/BR2009/000014 WO2009089605A1 (en) 2008-01-17 2009-01-16 Recombinant viral vectors and vaccine composition for leishmaniasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0800485A BRPI0800485B8 (pt) 2008-01-17 2008-01-17 vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose

Publications (4)

Publication Number Publication Date
BRPI0800485A2 BRPI0800485A2 (pt) 2009-09-01
BRPI0800485A8 true BRPI0800485A8 (pt) 2018-04-17
BRPI0800485B1 BRPI0800485B1 (pt) 2021-03-02
BRPI0800485B8 BRPI0800485B8 (pt) 2021-05-25

Family

ID=40885010

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0800485A BRPI0800485B8 (pt) 2008-01-17 2008-01-17 vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose

Country Status (4)

Country Link
CN (2) CN108014330A (pt)
BR (1) BRPI0800485B8 (pt)
MX (1) MX2010007876A (pt)
WO (1) WO2009089605A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016474A2 (pt) * 2018-02-13 2020-12-15 University Of Iowa Research Foundation Imunoterapia de leishmaniose
ES2795149B2 (es) 2020-06-08 2022-07-04 Univ Madrid Complutense Quimera sintetica multiepitopica como vacuna y tratamiento frente a leishmaniosis en mamiferos
CN113337542A (zh) * 2021-06-10 2021-09-03 山西大学 高效表达利什曼原虫pepck的人复制缺陷型重组腺病毒载体
CN115785282B (zh) * 2022-10-28 2025-01-14 杭州爱谨生物科技有限公司 犬源性利什曼原虫重组蛋白及其编码基因、制备方法和应用
KR20240176109A (ko) 2023-06-14 2024-12-24 경희대학교 산학협력단 피부 리슈만편모충의 LaPSA를 발현하는 재조합 바이러스 유사입자 백신

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT716697E (pt) * 1993-09-03 2003-08-29 Univ Mcgill Genes e proteinas de leishmania expressos diferencialmente
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6638517B2 (en) * 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ES2109189B1 (es) * 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
MXPA03008832A (es) * 2001-03-29 2004-05-05 Univ Mcgill Vacunas contra leishmania.
EP1771571A2 (en) * 2004-07-30 2007-04-11 Targeted Genetics Corporation Recombinant aav based vaccine methods

Also Published As

Publication number Publication date
WO2009089605A1 (en) 2009-07-23
MX2010007876A (es) 2011-03-03
BRPI0800485A2 (pt) 2009-09-01
CN102036681A (zh) 2011-04-27
BRPI0800485B8 (pt) 2021-05-25
CN108014330A (zh) 2018-05-11
BRPI0800485B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
BRPI0518146A (pt) kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
BR112014011229A2 (pt) composições e métodos para o tratamento de citomegalovírus
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
MX380483B (es) Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
AR090611A1 (es) Vacuna contra mycoplasma hyopneumoniae
BRPI0800485A8 (pt) vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
CA2763359C (en) New human rotavirus strains and vaccines
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
CR11307A (es) Vacunas
AR080111A1 (es) Metodos y composiciones de inmunizacion
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
EA200701128A1 (ru) Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
NO20074855L (no) Anvendelse av et modifisert poxvirus for den rapide induksjonen av immunitet mot et poxvirus eller andre smittsomme midler
PE20081687A1 (es) Proteina de fusion
EA201690115A1 (ru) Комбинированные иммуногенные композиции
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
BR112012029633A8 (pt) Vetores do parapoxvírus contendo antígeno do vírus da raiva.
MX2019007924A (es) Vacunas contra la influenza.
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B03H Publication of an application: rectification [chapter 3.8 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06V Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/01/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2810 DE 12-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.